Explain calcium channel blockers and vasodilators in antihypertensive drugs
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have excellent, comprehensive material. Let me now compile the full answer.
Calcium Channel Blockers (CCBs) and Vasodilators in Antihypertensive Therapy
CALCIUM CHANNEL BLOCKERS (CCBs)
Mechanism of Action
CCBs lower blood pressure by inhibiting calcium influx into arterial smooth muscle cells through voltage-gated L-type calcium channels. Reduced intracellular calcium leads to smooth muscle relaxation, peripheral vasodilation, and a fall in systemic vascular resistance.
- Katzung's Basic and Clinical Pharmacology, 16e
Classification and Drugs
| Subclass | Agents |
|---|---|
| Dihydropyridines (DHPs) | Amlodipine, felodipine, nifedipine, nicardipine, clevidipine, isradipine, nisoldipine |
| Non-dihydropyridines | Verapamil (phenylalkylamine), Diltiazem (benzothiazepine) |
All three subclasses are equally effective at lowering blood pressure, but they differ significantly in their cardiac effects.
Hemodynamic Differences
Dihydropyridines are highly selective as vasodilators with minimal cardiac depressant effects. Because of this vasoselectivity, they trigger reflex sympathetic activation - a slight compensatory tachycardia that maintains or increases cardiac output. This is why short-acting nifedipine can be problematic.
Verapamil has the greatest myocardial depressant effect - it slows heart rate, reduces AV conduction, and may decrease cardiac output. It is the most negatively chronotropic and inotropic of the CCBs.
Diltiazem is intermediate between the two.
- Katzung's Basic and Clinical Pharmacology, 16e
Clinical Use
Indications:
- Hypertension (first-line, especially in elderly and Black patients)
- Angina pectoris
- Certain arrhythmias (verapamil, diltiazem)
- Hypertensive emergencies (IV nicardipine, clevidipine)
Key principle: Short-acting oral dihydropyridines (especially immediate-release nifedipine) should not be used for chronic hypertension due to epidemiologic studies showing increased risk of myocardial infarction and mortality. Sustained-release formulations or long-acting agents (amlodipine) provide smoother blood pressure control and are preferred.
IV use: Nicardipine (infused at 2-15 mg/h) and clevidipine (starting at 1-2 mg/h, titrating to 4-6 mg/h) are used for acute hypertension when oral therapy is not feasible. Clevidipine has a very rapid onset and is used in perioperative hypertension.
- Katzung's Basic and Clinical Pharmacology, 16e
Adverse Effects
| Effect | Agent |
|---|---|
| Peripheral edema, flushing, headache | DHPs (vasodilatory effects) |
| Reflex tachycardia | DHPs |
| Bradycardia, AV block, negative inotropy | Verapamil, diltiazem |
| Constipation | Verapamil (classic) |
| Gingival hyperplasia | All CCBs (rare) |
Contraindication: Non-DHP CCBs (verapamil/diltiazem) are generally contraindicated in cardiac amyloidosis because they can bind amyloid fibrils (demonstrated in AL amyloidosis), and are contraindicated alongside IV beta-blockers due to severe bradycardia risk.
- Braunwald's Heart Disease, 2 Vol Set and Tintinalli's Emergency Medicine
VASODILATORS
Vasodilators act directly on vascular smooth muscle to lower peripheral resistance. They are subdivided based on which part of the vasculature they act on.
A. Arterial Vasodilators
Hydralazine
Mechanism: Hydralazine's exact mechanism is not fully understood. It is thought to reduce intracellular calcium in arteriolar smooth muscle. It also has antioxidant properties - by inhibiting oxidases, it prevents breakdown of endogenous and exogenous nitric oxide (NO), thereby enhancing NO-mediated vasodilation via cGMP. It acts selectively on arterioles (precapillary resistance vessels), not veins.
Hemodynamic effects: Selective dilation of arterioles causes a fall in afterload and a rise in cardiac output. Because veins are not dilated, LV preload is relatively preserved. The drop in resistance triggers baroreceptor-mediated reflex tachycardia, which can worsen myocardial ischemia. Because it dilates coronary, cerebral, and renal circulations preferentially, postural hypotension is NOT a major problem (unlike venodilators).
Pharmacokinetics:
- Oral bioavailability varies: ~16% in fast acetylators, ~35% in slow acetylators (genetically determined N-acetylation)
- Short half-life (~1 hour), but antihypertensive effect lasts up to 12 hours
- Dosed 2-4 times daily
Therapeutic uses:
- No longer first-line for hypertension
- Hypertensive emergencies in pregnancy/preeclampsia (drug of choice in this context)
- Heart failure in African-American patients: Fixed-dose hydralazine + isosorbide dinitrate (BiDil) improves symptoms and survival in self-identified Black patients with HFrEF already on a beta-blocker + ACE inhibitor/ARB
- Patients intolerant of ACE inhibitors or ARBs
Adverse effects:
-
Headache, dizziness, flushing, hypotension
-
Reflex tachycardia - requires co-administration with a beta-blocker
-
Edema - requires co-administration with a diuretic
-
Drug-induced lupus (SLE-like syndrome) - particularly with high doses (>200 mg/day). Risk is lower in fast acetylators
-
Myocardial ischemia (from reflex sympathetic activation) - use with caution in CAD
-
Goodman & Gilman's Pharmacological Basis of Therapeutics, Lippincott Illustrated Reviews: Pharmacology
Minoxidil
Mechanism: Minoxidil (as its active sulfated metabolite) opens ATP-sensitive potassium channels in smooth muscle, causing membrane hyperpolarization and arteriolar dilation. It is a potent, direct-acting arterial vasodilator.
Use: Reserved for severe, refractory hypertension not controlled by other agents. Always used with a beta-blocker (to block reflex tachycardia) and a loop diuretic (to block fluid retention).
Adverse effects:
- Reflex tachycardia
- Fluid retention (sometimes severe)
- Hypertrichosis (excessive hair growth) - topical form (Rogaine) exploits this for alopecia treatment
- Pericardial effusion (with long-term use)
B. Arterial and Venous Dilators (Balanced Vasodilators)
These drugs act on both arterial and venous sides of the circulation.
Sodium Nitroprusside
Mechanism: Nitroprusside dissociates spontaneously upon contact with sulfhydryl groups on cell walls to release NO and cyanide. The NO activates soluble guanylate cyclase (sGC), increases intracellular cGMP, activates protein kinase G, and causes release of intracellular calcium - producing smooth muscle relaxation and dilation of both arteries AND veins. It is the most balanced arterial/venous dilator.
Use:
- IV only, for hypertensive emergencies when other agents fail
- Requires invasive arterial blood pressure monitoring to prevent "overshoot" hypotension
- Used in aortic dissection in combination with esmolol (a beta-blocker) to achieve BP targets at lower doses
Pharmacokinetics: Ultra-short acting; onset within seconds, duration 1-2 minutes. Requires continuous infusion.
Cyanide toxicity: Nitroprusside is metabolized to cyanide, which reacts with thiosulfate to form thiocyanate for renal excretion. When thiosulfate stores are depleted (high doses, prolonged infusion, renal/hepatic insufficiency), cyanide accumulates. The maximum dose is 10 mcg/kg/min for no more than 10 minutes.
Adverse effects: Hypotension, cyanide/thiocyanate toxicity, methemoglobinemia (rare), tachyphylaxis, increased intracranial pressure.
- Tintinalli's Emergency Medicine, Lippincott Illustrated Reviews: Pharmacology
Nitroglycerin (IV)
Mechanism: Same NO/cGMP/PKG pathway as nitroprusside. However, nitroglycerin is a preferential venodilator at standard doses, with arterial dilation only at very high doses.
Effect: Reduces venous return (preload) more than afterload. This reduces cardiac workload and is favorable in myocardial ischemia.
Use: First-line IV agent only in heart failure with hypertension and acute coronary syndromes because of its favorable effects on coronary blood flow. A poor choice for other hypertensive emergencies because reduced preload in a volume-depleted hypertensive patient can cause severe hypotension.
Adverse effects: Hypotension, reflex tachycardia, headache (from venodilation), tolerance with continuous infusion.
COMPARISON SUMMARY
| Feature | CCBs (DHPs) | CCBs (Non-DHP) | Hydralazine | Nitroprusside | Nitroglycerin |
|---|---|---|---|---|---|
| Site of action | Arterial SM | Arterial SM + heart | Arterioles | Arteries + veins | Veins >> arteries |
| Mechanism | Block L-type Ca²+ channel | Block L-type Ca²+ channel | NO enhancement + Ca²+ reduction | NO via sGC/cGMP | NO via sGC/cGMP |
| Cardiac effects | Reflex tachycardia | Bradycardia, neg. inotrope | Reflex tachycardia | Reflex tachycardia | Reduced preload |
| Route | Oral (IV for nicardipine, clevidipine) | Oral (IV available) | Oral or IM/IV | IV only | IV |
| Key use | 1st-line HTN, angina | HTN, arrhythmias, angina | Pregnancy HTN, HF (with ISDN) | Refractory hypertensive emergency | ACS, acute HF |
| Signature toxicity | Pedal edema, flushing | AV block, constipation | Drug-induced lupus | Cyanide toxicity | Tolerance, headache |
Key teaching points:
- CCBs are first-line antihypertensives; always use long-acting or sustained-release formulations for chronic HTN, not short-acting nifedipine.
- Direct vasodilators (hydralazine, minoxidil) must always be combined with a beta-blocker and diuretic to blunt reflex tachycardia and fluid retention.
- Nitroprusside and IV nitrates are reserved for hypertensive emergencies and acute decompensated heart failure.
- The hydralazine + isosorbide dinitrate combination (BiDil) has a specific evidence-based role in HFrEF in African-American patients.
Sources: Katzung's Basic and Clinical Pharmacology, 16e | Goodman & Gilman's The Pharmacological Basis of Therapeutics | Lippincott Illustrated Reviews: Pharmacology | Tintinalli's Emergency Medicine: A Comprehensive Study Guide
This is a shared conversation. Sign in to Orris to start your own chat.